Acute Leukemia News

  • Alert Niraparib Approved for Ovarian Cancer Maintenance Tx Niraparib Approved for Ovarian Cancer Maintenance Tx Unlike other PARP inhibitors, niraparib was active both in patients with and those without BRCA mutations, and has been welcomed as a 'significant step forward.'
  • Seattle Genetics to Resume Trials as FDA Lifts Clinical Hold Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.
 

Acute Leukemia Perspective

 

Acute Leukemia Journal Articles